Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)

Background Esophageal cancer ranks as the seventh most prevalent cancer globally and is the sixth leading cause of cancer-related deaths, accounting for over half a million deaths annually. Esophageal Squamous Cell Carcinoma (ESCC) is one of the primary types of esophageal cancer, particularly prevalent in Asian regions. For patients with unresecta...

Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Academic Background Ovarian cancer is one of the most common malignancies of the female reproductive system. Despite recent advancements in treatment, the recurrence rate remains high, particularly in patients with late relapse. Platinum-based chemotherapy (CT) is the standard treatment for ovarian cancer, and poly (ADP-ribose) polymerase (PARP) in...